Lv3
374 积分 2022-07-29 加入
Finerenone in Persons with Chronic Kidney Disease without Diabetes
5天前
已完结
From mechanism to clinic: A call for actionable strategies to optimize finerenone and SGLT2i complementary therapy in T2DM-related CKD
18天前
已完结
Finerenone: kidney protection beyond type 2 diabetes
18天前
已完结
Benefits of finerenone treatment across chronic kidney disease aetiologies
18天前
已完结
Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis
1个月前
已完结
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
1个月前
已完结
Urine as a source of biomarkers and biological knowledge in chronic kidney disease
1个月前
已完结
The global epidemiology of acute kidney injury: challenges and opportunities
1个月前
已完结
Multifactorial chronic kidney disease and the kidney capacity–workload balance
1个月前
已完结
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
1个月前
已完结
皖公网安备34019202002308
